(R)-Roscovitine (CAS: 186692-46-6)

• 価格
• 製品情報

価格

目次に戻る

製品情報

商品コード	MR-C0001
品名	(R)-Roscovitine
分子式	C19H26N6O
分子量	354.5
CAS	186692-46-6
構造式
純度	≥99% (NMR)
形状	White to off-white solid.
別名	Seliciclib; CYC201; 6-Benzylamino-2-(R)-[(1-ethyl)-2-hydroxyethylamino]-9-isopropylpurine
特長	Potent and selective inhibitor of cyclin dependent kinases CDK1, CDK2, CDK5, CDK7 and CDK9. Pyridoxal kinase (PDXK) inhibitor. Triggers cell apoptotic cell death. Down-regulates Mcl-1 and MYCN. Anticancer compound. Kills chronic lymphocytic leukemia (LLC) cells and slows tumor growth in mouse xenografts. Inhibits cysts formation in culture and in polycystic kidney disease (PKD) mouse models. Potential anti-inflammatory compound that can influence the resolution of inflammation. Potential antidiabetic compound. Shown to protect pancreatic β-cells from glucotoxicity and increase insulin secretion. Shows antiviral properties. Neuroprotective in brain trauma. Has positive effects on Timothy syndrome cells. Used for cloning of mammals by synchronization of nucleus donor cells. Provides neuroprotection in experimental traumatic brain injury.
文献	Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5: L. Meijer, et al.; Eur. J. Biochem. 243, 527 (1997) Chemical inhibitors of cyclin-dependent kinases: L. Meijer and S.H. Kim; Meth. Enzymol. 283, 113 (1997) Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine: WF. De Azevedo, et al.; Eur. J. Biochem. 243, 518 (1997) Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of Herpes simplex virus and Human immunodeficiency virus type 1 by targeting cellular, not viral, proteins: L.M. Schang, et al.; J. Virol. 76, 7874 (2002) Enhanced survivability of cloned calves derived from roscovitine-treated adult somatic cells: J. Gibbons, et al.; Biol. Reprod. 66, 895 (2002) Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials: L. Meijer & E. Raimond; Acc. Chem. Res. 36, 417 (2003) Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives: L. Tang, et al.; J. Biol. Chem. 280, 31220 (2005) Roscovitine targets, protein kinases and pyridoxal kinase: S. Bach, et al.; J. Biol. Chem. 280, 31208 (2005) Inhibition of cyclin-dependent kinase 5 activity protects pancreatic beta cells from glucotoxicity: M. Ubeda, et al.; J. Biol. Chem. 281, 28858 (2006) Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis: A.G. Rossi, et al.; Nature Med. 12, 1056 (2006) Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor Roscovitine: N.O. Bukanov, et al.; Nature 444, 949 (2006) Production of cloned horse foals using roscovitine-treated donor cells and activation with sperm extract and/or ionomycin: K. Hinrichs, et al.; Reproduction 134, 319 (2007) CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases: K. Bettayeb, et al.; Oncogene 27, 5797 (2008) Practical Synthesis of Roscovitine and CR8: N. Oumata, et al.; Org. Process Res. Dev. 13, 641 (2009) CDK inhibitors Roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells: K. Bettayeb, et al.; Genes & Cancer 1, 369 (2010) Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome: M. Yazawa; Nature 471, 230 (2011) CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD: N.O. Bukanov, et al.; Cell Cycle 11, 4040 (2012) Selective CDK inhibitor limits neuroinflammation and progressive neurodegeneration after brain trauma: S.V. Kabadi, et al.; J. Cereb. Blood Flow Metab. 32, 137 (2012) Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism: C. Norez, et al.; Br. J. Pharmacol. 171, 4831 (2014)

目次に戻る